![](/wp-content/uploads/2024/04/Screenshot-2024-04-24-at-4.28.03%E2%80%AFPM.png)
$599
Study on Eligible Wegovy Patients through Medicare; Roche Q1 ’24 Earnings
Two cardiometabolic-related news items have been observed: a recent study from Kaiser showed that approximately 3.6M overweight or obese patients with heart conditions insured under Medicare could be eligible for Wegovy (view article); and Roche hosted its Q1 ’24 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective news items.